Executive Management

Meet our Management

Lundbeck’s Executive Management works closely together to deal with the operations and strategy that affect the entire company. These members are led by Charl van Zyl, President and CEO. 

Charl van Zyl

President & CEO, Born 1967

Charl van Zyl joined Lundbeck as President & CEO in September 2023. He brings more than 23 years of experience from commercial international management roles within the pharmaceutical industry, most recently in the field of immunology and neurology from UCB where he served as Executive Vice President (EVP) and Head of Neurology globally, responsible for corporate activities in Europe and international markets.

 

Besides UCB where he previously also held a position as Chief Operating Officer, his career includes positions such as EVP at BSN Medical, Corporate VP & Commercial Leader EMEA at Bausch & Lomb, CEO at JADO Technologies, Head of Marketing and Sales at Novartis Pharma and Business Unit Manager at Eli Lilly and Company.

 

Charl is South African and holds a degree in Medical Biochemistry from the University of Cape Town, South Africa. He has lived and worked in South Africa, United States, Japan, Switzerland, Belgium and now Denmark.

Lars Bang

Executive Vice President, Product Development & Supply, Born 1962

Having completed his degree, Lars Bang began his career at Lundbeck in 1988 as a trainee in R&D. Subsequently, he has head R&D Planning, Corporate Planning and Strategy, Lundbeck España S.A, Group Sales & Marketing. In 2003 he was appointed Group Senior Vice President Supply Operations & Engineering.

 

Lars holds a Master of Science degree in Engineering from the Technical University of Denmark and a Bachelor of Commerce degree in Marketing from the Copenhagen Business School.

Thomas Gibbs

Executive Vice President, Head of Lundbeck U.S., born 1971

Tom joined Lundbeck in February 2023 as an accomplished executive with more than 25 years of diverse corporate, general management and commercial leadership experience, including roles in Executive Management, Marketing, Sales, Commercial Operations, Customer Insights and Analytics and Finance at small, mid-size and large pharmaceutical companies. Prior to Lundbeck, Tom served as Chief Executive Officer and Global Business Leader of Vectura Inc.  Prior to his role at Vectura Inc., Tom held several Chief Commercial Officer roles, developing Commercial strategy and overseeing execution for U.S., Canadian and European markets at pharmaceutical companies with strong central nervous system (CNS) franchises, including a role as Chief Commercial Officer at Sunovion. He has also served as Head of General Medicines in the U.S. for Takeda.

 

Tom holds a BS in Economics with a dual concentration in finance and marketing from the Wharton School of the University of Pennsylvania and an M.B.A. from the Wharton School of Business.

Joerg Hornstein

CFO & Executive Vice President, Corporate functions, Born 1977

Joerg Hornstein started his career with Merck KGaA, where he spent 12 years in financial roles of increasing responsibility across different businesses, including roles at the Headquarters in Germany, as well as in Indonesia, China and the USA. He has proven experience in executive management roles and as a principal financial advisor to Boards of Directors. Before joining Lundbeck in August 2022, Joerg was with AC Immune SA as Executive Vice President and Chief Financial Officer since 2017, where he oversaw Finance and various corporate functions. Prior to AC Immune, he served as Senior Vice President and Head of Group Controlling for Unternehmensgruppe Theo Mueller.

 

Joerg is a German national. He holds a Bachelor of Business Administration from Baylor University – Hankamer School of Business, Texas, US and an MBA with Distinction from London Business School, UK.

Keld Flintholm Jørgensen

Executive Vice President, Corporate Strategy & Business Development, Born 1971

Keld Flintholm Jørgensen began his career at Arthur Andersen Corporate Assurance Services in Copenhagen. In 2000, he moved to F. Hoffmann La Roche’s headquarter in Basel, Switzerland, where he held different roles within Group risk management and Strategic Planning for the Pharma Division. In 2005, he relocated to the Baltics and became part of the leadership team responsible for established the first Roche sales affiliates in the region. Subsequently, he returned to Switzerland as Head of Finance and Business Partnering for the Swiss sales affiliate. From 2011, he moved to Roche Pharma Partnering as Director Strategic Partnering and successfully executed multiple strategic projects, partnering agreements and M&A deals across different therapy areas, including neuroscience. In 2017, he was promoted to Global Head Strategic Partnering at Roche and a member of the Late Stage Portfolio Committee. In April 2019, he joined Lundbeck as Executive Vice President and Chief Business Officer.

 

Keld holds a BSc in Economics & Business Administration and a MSc in Business Economics & Auditing from Copenhagen Business School. 

 

Keld is a Member of the Board of Directors of Scandion Oncology.

Johan Luthman

Executive Vice President, R&D, Born 1959

In 1991, Johan Luthman began his career in the pharmaceutical industry in Astra, later AstraZeneca. In 2005, Johan joined Serono as Head of Neuroscience & Immunology Research, and subsequently, in MerckSerono, as Therapy Area Head, Neurology & Immunology. In 2009, he became CEO of biotech start-up GeNeuro. In late 2009, Johan joined Merck as VP & Franchise Integrator for Neuroscience and Ophthalmology. In 2014, he came to Eisai where he was Senior Vice President and Head of Clinical Development. Johan joined Lundbeck as Executive Vice President, R&D in March 2019.

 

Johan is a Swedish national and is trained as a Doctor of Dental Sciences from the Karolinska Institute, Sweden. He also holds a PhD in Neurobiology and Histology as well as an Associate Professor title from the Karolinska Institute, Sweden.

 

Johan is a Member of the Board of Directors of Brain+.

Jacob Tolstrup

Executive Vice President, Commercial Operations, Born 1972

Jacob Tolstrup began his career with Abbott Laboratories in 1997. In 1999, he joined Lundbeck and has since been working in several positions including Finance, Investor Relations and Corporate Communication and has worked in Lundbeck’s affiliate in the US for approximately four years. Before taking on the role as Executive Vice President, Commercial Operations, Jacob was head of Corporate Functions which comprised of Corporate Business Development, Corporate Human Resources, Investor Relations and Corporate Communication & Public Affairs.

 

Jacob holds a Master of Science in Business Administration & Commercial Law from Aalborg University, Denmark and an MBA from European Business College, Munich, Germany.

 

Jacob is Chairman of the Board of Directors of Pharmacosmos A/S.

More from Lundbeck

Business Development

Partnerships are a key pillar in our strategy to become leaders in brain health.

Our Commitment

Bettering the lives of people living with brain diseases requires a multifaceted approach. 

Sustainability

Lundbeck remains committed to sustainability through our strong strategy.